MovDisordV3, Main, Exploration, bibRecord, 000023

Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.

Identifieur interne : 000023 ( Main/Exploration ); précédent : 000022; suivant : 000024

Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.

Auteurs : Werner Poewe [Autriche] ; Philipp Mahlknecht [Autriche] ; Florian Krismer [Autriche]

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.

RBID : pubmed:26227071

Abstract

Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are relentlessly progressive neurodegenerative diseases leading to severe disability and ultimately death within less than 10 y. Despite increasing efforts in basic and clinical research, effective therapies for these atypical parkinsonian disorders are lacking. Although earlier small clinical studies in MSA and PSP mainly focused on symptomatic treatment, advances in the understanding of the molecular underpinnings of these diseases and in the search for biomarkers have paved the way for the first large and well-designed clinical trials aiming at disease modification. Targets of intervention in these trials have included α-synuclein inclusion pathology in the case of MSA and tau-related mechanisms in PSP. Since 2013, four large randomized, placebo-controlled, double-blind disease-modification trials have been completed and published, using rasagiline (MSA), rifampicin (MSA), tideglusib (PSP), or davunetide (PSP). All of these failed to demonstrate signal efficacy with regard to the primary outcome measures. In addition, two randomized, placebo-controlled, double-blind trials have studied the efficacy of droxidopa in the symptomatic treatment of neurogenic orthostatic hypotension, including patients with MSA, with positive results in one trial. This review summarizes the design and the outcomes of these and other smaller trials published since 2013 and attempts to highlight priority areas of future therapeutic research in MSA and PSP. © 2015 International Parkinson and Movement Disorder Society.

DOI: 10.1002/mds.26334
PubMed: 26227071

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University of Innsbruck, Innsbruck</wicri:regionArea>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Mahlknecht, Philipp" sort="Mahlknecht, Philipp" uniqKey="Mahlknecht P" first="Philipp" last="Mahlknecht">Philipp Mahlknecht</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University of Innsbruck, Innsbruck</wicri:regionArea>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Krismer, Florian" sort="Krismer, Florian" uniqKey="Krismer F" first="Florian" last="Krismer">Florian Krismer</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University of Innsbruck, Innsbruck</wicri:regionArea>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26227071</idno>
<idno type="pmid">26227071</idno>
<idno type="doi">10.1002/mds.26334</idno>
<idno type="wicri:Area/PubMed/Corpus">000093</idno>
<idno type="wicri:Area/PubMed/Curation">000093</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000022</idno>
<idno type="wicri:Area/Ncbi/Merge">004425</idno>
<idno type="wicri:Area/Ncbi/Curation">004425</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004425</idno>
<idno type="wicri:Area/Main/Merge">000023</idno>
<idno type="wicri:Area/Main/Curation">000023</idno>
<idno type="wicri:Area/Main/Exploration">000023</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University of Innsbruck, Innsbruck</wicri:regionArea>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Mahlknecht, Philipp" sort="Mahlknecht, Philipp" uniqKey="Mahlknecht P" first="Philipp" last="Mahlknecht">Philipp Mahlknecht</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University of Innsbruck, Innsbruck</wicri:regionArea>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Krismer, Florian" sort="Krismer, Florian" uniqKey="Krismer F" first="Florian" last="Krismer">Florian Krismer</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University of Innsbruck, Innsbruck</wicri:regionArea>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are relentlessly progressive neurodegenerative diseases leading to severe disability and ultimately death within less than 10 y. Despite increasing efforts in basic and clinical research, effective therapies for these atypical parkinsonian disorders are lacking. Although earlier small clinical studies in MSA and PSP mainly focused on symptomatic treatment, advances in the understanding of the molecular underpinnings of these diseases and in the search for biomarkers have paved the way for the first large and well-designed clinical trials aiming at disease modification. Targets of intervention in these trials have included α-synuclein inclusion pathology in the case of MSA and tau-related mechanisms in PSP. Since 2013, four large randomized, placebo-controlled, double-blind disease-modification trials have been completed and published, using rasagiline (MSA), rifampicin (MSA), tideglusib (PSP), or davunetide (PSP). All of these failed to demonstrate signal efficacy with regard to the primary outcome measures. In addition, two randomized, placebo-controlled, double-blind trials have studied the efficacy of droxidopa in the symptomatic treatment of neurogenic orthostatic hypotension, including patients with MSA, with positive results in one trial. This review summarizes the design and the outcomes of these and other smaller trials published since 2013 and attempts to highlight priority areas of future therapeutic research in MSA and PSP. © 2015 International Parkinson and Movement Disorder Society.</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
</country>
<region><li>Tyrol (Land)</li>
</region>
<settlement><li>Innsbruck</li>
</settlement>
<orgName><li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
</region>
<name sortKey="Krismer, Florian" sort="Krismer, Florian" uniqKey="Krismer F" first="Florian" last="Krismer">Florian Krismer</name>
<name sortKey="Mahlknecht, Philipp" sort="Mahlknecht, Philipp" uniqKey="Mahlknecht P" first="Philipp" last="Mahlknecht">Philipp Mahlknecht</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000023 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000023 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:26227071
   |texte=   Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:26227071" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.

Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.